Dr. Schulz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UT Physicians Neurocognitive Disorders
1941 E Rd, Ste 4358
Houston, TX 77054Phone+1 713-486-0500Fax+1 713-383-1435
Summary
- Dr. Paul Schulz is a neurologist in Houston, TX and is affiliated with Memorial Hermann - Texas Medical Center. He received his medical degree from Boston University School of Medicine and has been in practice 33 years. He specializes in neurodegenerative and dementia & geriatrics and is experienced in amyotrophic lateral sclerosis, dementia, alzheimer's disease, risk management, and cognitive disorders.
Education & Training
- Baylor College of MedicineResidency, Neurology, 1985 - 1988
- Boston VA Healthcare System (Brockton-West Roxbury)Internship, Internal Medicine, 1984 - 1985
- Boston UniversityB.A., Medical Sciences and Psychology, Magna Cum Laude, 1977 - 1984
- Boston University School of MedicineClass of 1984
Certifications & Licensure
- TX State Medical License 1988 - 2026
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- “Dean’s Excellence in Teaching Award” UTHealth, 2022
- "Dean's Teaching Excellence Award" UTHealth, 2012
- "Doctor's Choice" Health and Fitness Magazine, 2009
- Join now to see all
Clinical Trials
- Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Start of enrollment: 2015 Jul 01
- A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). Start of enrollment: 2016 Mar 22
- A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease Start of enrollment: 2016 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Serum metabolome profiling in patients with mild cognitive impairment reveals sex differences in lipid metabolism.Rocio Diaz Escarcega, Vijay Kumar M J, Vasilia E Kyriakopoulos, Guadalupe J Ortiz, Aaron M Gusdon
Neurobiology of Disease. 2024-11-29 - Serum metabolome profiling in patients with mild cognitive impairment reveals sex differences in lipid metabolism.Rocio Diaz Escarcega, M J Vijay Kumar, Vasilia E Kyriakopoulos, Guadalupe J Ortiz, Aaron M Gusdon
Biorxiv. 2024-11-13 - 1 citationsAssociation between risk of Alzheimer's disease and related dementias and angiotensin receptor Ⅱ blockers treatment for individuals with hypertension in high-volume cl...Sori Kim Lundin, Xinyue Hu, Jingna Feng, Karl Kristian Lundin, Lu Li
Ebiomedicine. 2024-11-01
Journal Articles
- Delirious Mania in Bipolar DisorderKimm, TS, Okusaga OO, and Schulz PE, Prim Care Companion CNS Disord, 1/2/2017
- Hippocampal Sclerosis in Older Patients: Practical Examples and Guidance With a Focus on Cerebral Age-Related TDP-43 With SclerosisCykowski MD, Powell SZ, Schulz PE, Takei H, Rivera AL, Jackson RE, Roman G, Jicha GA, and Nelson PT, Arch Pathol Lab Med, 1/1/2017
- NeuropsychiatryArora G, Schulz PE, Neurology Secrets, 1/1/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Deep Brain Stimulation of the Medial Forebrain Bundle: Significant Responses in Treatment Resistant Depression.Fenoy AJ, Schulz P, Selvaraj S, Burrows, Zunta-Soares G, Quevedo J, Soares JC, North American Neuromodulation Society (NANS) 21st Annual Meeting, Las Vegas, NV, 1/11/2018
- Evidence for neuroinflammation in semantic dementia.Pascual MB, Roman GC, Yu M, Pal N, Rockers ED, Fregonara Z, Funk Q, Schulz PE, and Masdeu J, Human Amyloid Imaging Conference, 1/1/2018
- Nonfluent variant of primary progressive aphasia: Tau deposition in the language network.Pascual B, Zanotti-Fregonara P, Funk Q, Rockers E, Pal N, Yu M, Spann B, Schulz P, Masdeu J, American Academy of Neurology (AAN) Meeting, 1/1/2017
- Join now to see all
Lectures
- "Lewy Body Dementia"Austin, TX - 1/25/2017
- "Update on Neuroimaging and Therapeutic Trials in Alzheimer's Disease"Austin, TX - 1/25/2017
- "Recent Advances in Diagnosing and Treating AD"University of Texas Medical Branch, Galveston, TX - 1/22/2017
- Join now to see all
Other
- "Pimavanserin for Parkinson's Disease Psychosis."Schulz PE, Webinar with Fort Worth MDs
1/31/2017 - Commenting on the radio on "It's impossible to ignore this anymore': CTE study details devastating toll on football players."Schulz PE, News Talk 710 KURV
TX - 1/26/2017 - "Alzheimer's Day."Schulz PE, KRUV Radio
1/23/2017 - Join now to see all
Press Mentions
- What to Know About the Alzheimer’s DrugsNovember 6th, 2024
- Researchers Find a Critical Link Between Vaccinations and Alzheimer’s DiseaseOctober 27th, 2024
- First Infusion in Houston for New Alzheimer’s Drug Administered at UTHealth HoustonOctober 7th, 2024
- Join now to see all
Grant Support
- Pilot Study--Amyloid Mediated ToxicityNational Institute On Aging1995–2000
External Links
- All PubMed Publicationshttps://www.ncbi.nlm.nih.gov/myncbi/1d3Rdqa1xETkm7/bibliography/public/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: